Tests APG-2575 in adults with mild-to-moderate lupus
Tests the drug APG-2575 against a placebo in adults with mild-to-moderate lupus.
Plain-language title generated from the registry record
Registry title: A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06182969, who can take part
Where in China
- Renji Hospital Shanghai Jiaotong University School of MedicalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ascentage Pharma Group Inc.
- Trial code
- NCT06182969
- Record updated
- 16 December 2025
- Original description
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Inclusion: 1. Diagnosis of systemic lupus erythematosus for at least 6 months; 2. On stable treatment for systemic lupus erythematosus before first dose at least 28 days; 3. SLEDIA-2000 score: 4-12; 4.Other than systemic lupus erythematosus, subject should be in general good health.
Exclusion: 2. Significant autoimmune disease other than lupus; 3. Significant, uncontrolled or unstable disease in any organ; 1. Severe systemic lupus erythematosus.